Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of T-cell infusion, Aldesleukin (IL-2), and Utomilumab in recurrent ovarian cancer has completed …
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors [Phase 1]
This Phase 1 update describes the dose-escalation and expansion study of AROG4-01 in patients with advanced solid tumors, including mesothel…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living [NA]
This completed study assesses the feasibility and usability of a self-care app intended to enhance purposeful living for individuals with ov…
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer [Phase 1, Phase 2]
A Phase 1/2 trial of Maplirpacept in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer was terminated, …
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC [EARLY_Phase 1]
This clinical trial update reports completion of an early-phase 1 randomized study (IMPACT) evaluating novel therapeutic agents in women wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors [Phase 1]
A Phase I trial evaluating CCT303-406 in relapsed or refractory HER2-positive solid tumors is active but not recruiting, including gastric c…
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer
A clinical trial update focusing on validating the KELIM metric as a predictive and prognostic biomarker for maintenance PARP inhibitor ther…
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. [EARLY_Phase 1]
This is an early-phase exploratory study evaluating the safety and potential efficacy of Disitamab Vedotin in combination with Anlotinib Hyd…
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of ruxolitinib phosphate in combination with paclitaxel and carboplatin for S…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial [NA]
This document provides an update on the DISC-OVARY trial, which investigates a 3D bioprinted hormone-producing model for BRCA mutation carri…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study [Phase 2]
A Phase 2 neoadjuvant trial evaluating Olaparib in ovarian cancer (Stage IV) is currently not recruiting.
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
This clinical trial update notes a real-world evidence study in Poland evaluating niraparib maintenance therapy for newly diagnosed advanced…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. [Phase 1, Phase 2]
Clinical trial update reporting safety, pharmacokinetics, and efficacy findings for tinostamustine in patients with advanced solid tumors, i…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients [Phase 2]
This entry notes a Phase 2 clinical trial evaluating SSGJ-707 in advanced or recurrent gynecologic cancers, including endometrial cancer and…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy [NA]
A completed clinical trial evaluating the Halcyon 4.0 imaging system for patients receiving radiation therapy across several cancers.
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer [Phase 1]
A Phase 1 study evaluating pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with ovarian cancer…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer [Phase 3]
This Clinical Trials update reports a Phase 3 study evaluating chiauranib in combination with weekly paclitaxel for platinum-refractory or p…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Milademetan in Advanced/Metastatic Solid Tumors [Phase 2]
A Phase 2 trial of milademetan in advanced or metastatic solid tumors was terminated, with results posted in October 2024.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
This clinical trial is evaluating an ultrasensitive surface-enhanced Raman spectroscopy (SERS) platform with efficient enrichment of analyte…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. [NA]
A clinical trial update for MIRRORS-FROZEN, a study comparing open versus robotic surgery for complex pelvic adnexal masses up to 8 cm, curr…
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors [Phase 1]
A Phase 1 trial evaluating ZEN003694 in combination with niraparib for metastatic or recurrent solid tumors, including ovarian cancer, has b…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Systemic Inflammatory Biomarkers in Ovarian Cancer
A clinical trial investigating systemic inflammatory biomarkers in ovarian cancer has completed. The provided information does not include t…
-
CLINICAL_TRIALS trial_result · 2024-10-08Clinical Trial Update: P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 trial evaluating the P53MVA vaccine with pembrolizumab for recurrent platinum-resistant ovarian cancer, fallopian tube cancer, or pr…